Gilead To File Filgotinib For RA in 2019, Earlier Than Forecast

 
• By Kevin Grogan

Concerns the Galapagos-partnered JAK inhibitor would be held back by a testicular toxicity study have been calmed by positive FDA talks and a submission is due before the end of the year.

Question_Clock
No more questions about timing for filgotinib filing • Source: Shutterstock

More from Immunological

More from Therapy Areas